Literature DB >> 23424262

Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus.

Venkat Reddy, Sara Croca, Delia Gerona, Inmaculada De La Torre, David Isenberg, Vickie McDonald, Maria Leandro, Geraldine Cambridge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23424262     DOI： 10.1093/rheumatology/ket004

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  9 in total

1.  Kinetic changes of regulatory B10 cells in collagen-induced arthritis could be regulated by cytokines IFN-γ and TGF-β1.

Authors:  Zhaohui Zheng; Tao Liu; Xueyi Li; Jin Ding; Yuan Feng; Jinlin Miao; Xing Luo; Zhenbiao Wu; Ping Zhu
Journal:  Inflamm Res       Date:  2015-06-27       Impact factor: 4.575

2.  Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.

Authors:  F Mensah; A Bansal; S Berkovitz; A Sharma; V Reddy; M J Leandro; G Cambridge
Journal:  Clin Exp Immunol       Date:  2016-02-22       Impact factor: 4.330

3.  Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.

Authors:  Liliana Michelle Gomez Mendez; Matthew D Cascino; Jay Garg; Tamiko R Katsumoto; Paul Brakeman; Maria Dall'Era; Richard John Looney; Brad Rovin; Leonard Dragone; Paul Brunetta
Journal:  Clin J Am Soc Nephrol       Date:  2018-08-08       Impact factor: 8.237

4.  Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?

Authors:  Venkat R Reddy; Ruth J Pepper; Kavina Shah; Geraldine Cambridge; Scott R Henderson; Christian Klein; Loren Kell; Samuel J Taylor; David A Isenberg; Mark S Cragg; Maria J Leandro
Journal:  Rheumatology (Oxford)       Date:  2022-07-06       Impact factor: 7.046

5.  Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.

Authors:  Md Yuzaiful Md Yusof; Daniel Shaw; Yasser M El-Sherbiny; Emma Dunn; Andy C Rawstron; Paul Emery; Edward M Vital
Journal:  Ann Rheum Dis       Date:  2017-07-06       Impact factor: 19.103

6.  Rituximab levels are associated with the B cell homeostasis but not with the clinical response in patients with rheumatoid arthritis.

Authors:  Cèsar Díaz-Torné; Maria Àngels Ortiz; Mónica Sarmiento; César Díaz-López; Hèctor Corominas; Jordi Casademont; Silvia Vidal
Journal:  Eur J Rheumatol       Date:  2019-04-01

Review 7.  B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.

Authors:  Venkat Reddy; David Jayne; David Close; David Isenberg
Journal:  Arthritis Res Ther       Date:  2013-02-11       Impact factor: 5.156

8.  Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Venkat Reddy; Geraldine Cambridge; David A Isenberg; Martin J Glennie; Mark S Cragg; Maria Leandro
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

9.  Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human Plasma.

Authors:  Aurélien Millet; Nihel Khoudour; Dorothée Lebert; Christelle Machon; Benjamin Terrier; Benoit Blanchet; Jérôme Guitton
Journal:  Molecules       Date:  2021-03-04       Impact factor: 4.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.